{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:24:05Z","timestamp":1786728245667,"version":"build-2736575974"},"reference-count":24,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To report visual acuity (VA) outcomes following chemotherapy for optic pathway glioma (OPG) in children with or without neurofibromatosis type-1 (NF1) and to analyse associated risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective, multicentre, cohort study involving 155 children treated between September 2004 and December 2012. Initial and final VA was used for per-eye and per-subject analysis. Correlation tests were performed to determine whether initial VA predicted final VA. Logistic regression was used to determine whether age and tumour location were associated risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>90 children had complete ophthalmological data. At initiation of chemotherapy, 26% and 49% of eyes with NF1-OPG and sporadic OPG, respectively, had VA of \u22650.7\u2009log of the minimum angle of resolution (logMAR). At final visit, per eye, 49% had \u22640.2, 23% had 0.30\u20130.60 and 28% had VA\u22650.70\u2009logMAR in the NF1-OPG group. In the sporadic OPG group, per eye, 32% had \u22640.2, 11% had VA 0.30\u20130.60 and 57% had \u22650.70\u2009logMAR. Children with sporadic OPG, per eye, were significantly less likely to have VA outcomes \u22640.60\u2009logMAR compared with children with NF1-OPG (OR=0.30; 95% CI 0.16 to 0.56; P&lt;0.0001). Per subject, VA improved in 24%, remained stable in 35% and worsened in 41% of children with NF1-OPG and improved in 18%, remained stable in 43% and worsened in 39% of children with sporadic OPG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Children with and without NF1 demonstrated the same rate of VA improvement, stabilisation or worsening; however, children with sporadic OPG had a poorer VA outcome. Better initial VA, older age, absence of postchiasm tumour and presence of NF1 were associated with improved or stable VA outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2017-311305","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T17:20:45Z","timestamp":1516209645000},"page":"1367-1371","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":63,"title":["Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort"],"prefix":"10.1136","volume":"102","author":[{"given":"Kevin","family":"Falzon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Drimtzias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Picton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"2023012305101339000_102.10.1367.1","doi-asserted-by":"crossref","first-page":"e0127676","DOI":"10.1371\/journal.pone.0127676","article-title":"Mortality in children with optic pathway glioma treated with up-front BB-SFOP chemotherapy","volume":"10","author":"Rakotonjanahary","year":"2015","journal-title":"PLoS One"},{"key":"2023012305101339000_102.10.1367.2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11060-011-0783-2","article-title":"Characterization and outcomes of optic nerve gliomas: a population-based analysis","volume":"107","author":"Mishra","year":"2012","journal-title":"J Neurooncol"},{"key":"2023012305101339000_102.10.1367.3","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq092"},{"key":"2023012305101339000_102.10.1367.4","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1002\/cncr.29649","article-title":"Long-term visual outcome after chemotherapy for optic pathway glioma in children: Site and age are strongly predictive","volume":"121","author":"Dodgshun","year":"2015","journal-title":"Cancer"},{"key":"2023012305101339000_102.10.1367.5","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0b013e31822aef82"},{"key":"2023012305101339000_102.10.1367.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2011.09.003"},{"key":"2023012305101339000_102.10.1367.7","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.4.516"},{"key":"2023012305101339000_102.10.1367.8","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000435745.95155.b8"},{"key":"2023012305101339000_102.10.1367.9","unstructured":"Walker D . British Neuro-Oncology Society\/NCAT Rare Tumour Guidelines. Guidelines on the diagnosis and management of Optic Pathway Glioma, 2011. https:\/\/www.bnos.org.uk\/wp-content\/uploads\/2015\/08\/Optic-pathway-glioma-guidelines.pdf"},{"key":"2023012305101339000_102.10.1367.10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","article-title":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u226416\u00a0years) low grade glioma\u00a0- A final report","volume":"81","author":"Gnekow","year":"2017","journal-title":"Eur J Cancer"},{"key":"2023012305101339000_102.10.1367.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0042-6989(97)88335-6"},{"key":"2023012305101339000_102.10.1367.12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-016-2163-4","article-title":"Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1","volume":"129","author":"Wan","year":"2016","journal-title":"J Neurooncol"},{"key":"2023012305101339000_102.10.1367.13","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.3.268"},{"key":"2023012305101339000_102.10.1367.14","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos076"},{"key":"2023012305101339000_102.10.1367.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.12.035"},{"key":"2023012305101339000_102.10.1367.16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/archneurpsyc.1958.02340060003001","article-title":"Gliomas of the optic nerves","volume":"79","author":"Dodge","year":"1958","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"2023012305101339000_102.10.1367.17","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-013-0225-x"},{"key":"2023012305101339000_102.10.1367.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(94)70122-9"},{"key":"2023012305101339000_102.10.1367.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00852-7"},{"key":"2023012305101339000_102.10.1367.20","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22748"},{"key":"2023012305101339000_102.10.1367.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.03.028"},{"key":"2023012305101339000_102.10.1367.22","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2007-031"},{"key":"2023012305101339000_102.10.1367.23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/jamaophthalmol.2013.571","article-title":"Visual function and optic pathway glioma: a critical response","volume":"131","author":"Gutmann","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2023012305101339000_102.10.1367.24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1001\/2013.jamaophthalmol.519","article-title":"Visual function and optic pathway glioma: a critical response-reply","volume":"131","author":"Parsa","year":"2013","journal-title":"JAMA Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2017-311305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T13:11:54Z","timestamp":1674479514000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2017-311305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,17]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,9,24]]},"published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1136\/bjophthalmol-2017-311305"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311305","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,17]]}}}